한글목차

트롬빈 억제제 시장은 2025년 346억 8,000만 달러, 2032년에는 528억 4,000만 달러에 이를 것으로 예측되며, 2025-2032년 연간 평균 성장률(CAGR)은 6.2%를 나타낼 전망입니다.

트롬빈 억제제는 트롬빈에 결합하여 그 활성을 억제하고 혈전 형성을 방지하는 항응고제(또는 항응고제로 작용하는 약물의 일종)입니다. 동맥 및 정맥 혈전증 예방, 심부정맥 혈전증 예방 및 치료, 심방세동에서 혈전색전증 예방에 사용됩니다.

트롬빈 억제제로 치료할 수 있는 질환으로는 급성관상동맥증후군, 심장 혈전, 헤파린 유발 혈소판감소증(HIT), 정맥혈전색전증(VTE), 심방세동(Afib), 심부정맥혈전증(DVT), 폐색전증 등이 있습니다.

현재 의료진이 사용하는 직접 트롬빈 억제제에는 알가트로반(정맥주사), 비바리루딘(정맥주사), 다비가트란(정제) 등이 있습니다.

시장 역학

심부정맥혈전증(DVT), 폐색전증(PE), 심방세동(AF)의 유병률/발생률 증가, 안전하고 효과적인 치료법에 대한 수요 증가(전 세계 사람들의 인식 증가로 인한), 연구개발(R&D) 증가, 새로운 항응고제 도입이 세계 트롬빈 억제제 시장의 성장을 가속할 것으로 예측됩니다. 주요 요인입니다.

예를 들어, 2018년 6월 Mylan N.V.는 Angiomax의 제네릭 의약품인 Bivalirudin for Injection의 미국 출시를 발표했습니다. 이 제품은 250mg 단일 용량 바이알로, 환자에게 항응고제로 사용하기 위한 직접 트롬빈 억제제입니다. 미국 식품의약국(FDA)의 신약허가신청(ANDA) 승인을 받아 병원 및 의료기관을 대상으로 비발리루딘을 공급하고 있습니다.

본 조사의 주요 특징

• 세계의 트롬빈 억제제 시장을 상세하게 분석했으며, 예측 기간(2025-2032년) 시장 규모와 CAGR을 조사하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 트롬빈 억제제 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 보입니다.
• 세계 트롬빈 억제제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 트롬빈 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 규제 시나리오
• 제품 발매 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 인수합병(M&A) 시나리오

제4장 트롬빈 억제제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 트롬빈 억제제 시장, 유형별, 2020-2032년

• 서론
• 직접 트롬빈 억제제
• 간접 트롬빈 억제제

제6장 트롬빈 억제제 시장, 용도별, 2020-2032년

• 서론
• 심부정맥 혈전증(DVT)
• 폐색전증(PE)
• 심방세동(AF)
• 기타(뇌졸중 예방, 급성관 증후군 등)

제7장 트롬빈 억제제 시장, 지역별, 2020-2032년

• 서론
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • ASEAN 국가
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 남아프리카
  • 북아프리카
  • 중앙아프리카

제8장 경쟁 구도

• Eisai Co., Ltd.
• Merck & Co., Inc.
• Novartis International AG
• GlaxoSmithKline plc
• AbbVie Inc.
• Portola Pharmaceuticals, Inc.
• CSL Behring
• Johnson & Johnson
• Sanofi S.A.
• Bayer AG
• Pfizer Inc.
• Bristol Myers Squibb
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Company
• Aspen Pharmacare Holdings Limited

제9장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Thrombin Inhibitor Market is estimated to be valued at USD 34.68 Bn in 2025 and is expected to reach USD 52.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.

Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.

The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.

Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).

Market Dynamics:

The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.

For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).

Key features of the study:

• This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032)
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market

Detailed Segmentation:

• By Type:
  • Direct Thrombin Inhibitors
  • Indirect Thrombin Inhibitors
• By Application:
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Atrial Fibrillation (AF)
  • Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Portola Pharmaceuticals, Inc.
  • CSL Behring
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Pfizer Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company
  • Aspen Pharmacare Holdings Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Thrombin Inhibitor, By Type
  • Market Thrombin Inhibitor, By Application
  • Market Thrombin Inhibitor, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Thrombin Inhibitor Market, By Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2020 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Direct Thrombin Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Indirect Thrombin Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Thrombin Inhibitor Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2020 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Deep Vein Thrombosis (DVT)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Pulmonary Embolism (PE)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Atrial Fibrillation (AF)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Thrombin Inhibitor Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2020 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Portola Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Behring
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Daiichi Sankyo Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aspen Pharmacare Holdings Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us